Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
Ownership | 2026-03-18 4:01 pm | N/A 2034-07-08 | Agomab Therapeutics NV | AGMB | Epstein David R Director | 0 | $0 | 1,026,809 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A N/A | Agomab Therapeutics NV | AGMB | Knotnerus Tim Jasper Chief Executive Officer | 0 | $0 | 2,128,092 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2034-11-04 | Agomab Therapeutics NV | AGMB | Bond Colin Michael Director | 0 | $0 | 151,407 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2036-01-15 | Agomab Therapeutics NV | AGMB | Hammer Ohad Director | 0 | $0 | 27,921 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2034-07-08 | Agomab Therapeutics NV | AGMB | Kemula Pierre Thadee Victor Chief Financial Officer | 0 | $0 | 583,020 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2033-10-10 | Agomab Therapeutics NV | AGMB | Jahreis Angelika Martha Director | 0 | $0 | 154,992 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2031-03-05 | Agomab Therapeutics NV | AGMB | van der Horst Paul Henryk Chief Business Officer | 0 | $0 | 612,556 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2036-01-15 | Agomab Therapeutics NV | AGMB | Verduyn-van Weegen Felice Isabel Director | 0 | $0 | 32,700 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2031-03-05 | Agomab Therapeutics NV | AGMB | Borderias Andrea Saez Chief Development Officer | 0 | $0 | 586,154 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2031-03-05 | Agomab Therapeutics NV | AGMB | Lefever Ellen General Counsel | 0 | $0 | 457,304 (Direct) | View |
Ownership | 2026-03-18 4:01 pm | N/A 2029-03-14 | Agomab Therapeutics NV | AGMB | Wiesel Philippe Constantin Chief Medical Officer | 0 | $0 | 627,775 (Direct) | View |